Study Of The Expressions Of PTEN And MDM2 Protein In Ovary Carcinoma

[Objective]: Carcinoma of ovary is the most common malignant ovarian tumor. So far the pathogenesis of ovarian carcinoma, closely correlated with multigenic mutation, has not been identified. Researches reveal that tumor suppressing gene PTEN and oncogene MDM2 play important role in the regulation of growth, differentiation, apotosis, infiltration, metastasis on tumor cells and tumor angiogenesis. This experiment investigates the expression of PTEN and MDM2 in carcinoma of ovary , ovary tissue adjacent to carcinoma tissue and the normal ovary tissue, and probes into the relation of the clinical pathological fators of patients and the significance in the occurrence and development of ovarian carcinoma, and the influence to the prognosis of patients, with the hope to provide valuable biological index for early clinical diagnosis and prognosis judgment of ovarian carcinoma.[Methods]: The expressions of PTEN and MDM2 protein were evaluated in 62 ovarian carcinomas (including 22 serous cystadenocarcinoma, 20 mucinous cystadenocarcinoma, 20 endometrioid carcinoma ) , 15 ovary tissue adjacent to carcinoma tissue and 10 normal tissue by immunohistochemistry (SABC method).[Results]: The positive rate of PTEN in all the ovarian carcinoma patients was 33.9%, significantly lower than that in ovary tissue adjacent to carcinoma tissue (86.6%) and the normal ovary tissue (90 %) (P<0. 01), while positive rate of PTEN in adjacent to carcinomatissue and the normal ovary tissue have no evident difference (P>0. 05) . The positive rate of PTEN in serous cystadenocarcinoma , mucinous cystadenocarcinoma and endometrioid carcinoma were separately 36.4% (8/22), 35.0% (7/20), 36.5% (6/20), which have no evident difference (P>0. 05) .The positive rate of PTEN in Stage I and II ovary carcinoma tissue (53.3 %) was much higher than that in stage LII and IV carcinoma tissue(19. 4%) (P<0. 01). The positive rate of MDM2 in all the ovarian carcinoma patients was 69.4%, observably higher than that in ovary tissue adjacent to carcinoma tissue (0.06%)and the normal ovary tissue (0%) (P<0.01) , while positive rate of MDM2 in adjacent to carcinoma tissue and the normal ovary tissue have no evident difference ( P>0.05 ) . The positive rate of PTEN in serous cystadenocarcinoma , mucinous cystadenocarcinoma and endometrioid carcinoma were separately 68. 2% (15/22), 65. 0% (13/20), 75. 0% (15/20), which have no evident difference ( P>0. 05) . Correspondingly, the positive rate of MDM2 in stage I and II ovarian carcinoma tissue (53.8%) was markedly lower than that in Stage III and IV carcinoma tissue (80.6%) (P<0.01). The expression of PTEN was highly related with that of MDM2 (P<0.01).[Conclusions] : 1 . PTEN in ovary tissue adjacent to carcinoma tissue and the normal ovary tissue shows high expression, while in carcinoma tissue, it is weak expression or deletion. Contrarily, MDM2 in carcinoma tissue displays high expression, while in ovary tissue adjacent to carcinoma tissue and the normal ovary tissue, it is weak expression or deletion. The expression of PTEN and MDM2 is negatively correlated, which indicates that deletion or weak expression of PTEN and over-expression of MDM2 play a certain role in the occurrence of primary ovary carcinoma.2. The positive rate of PTEN in stage I and II ovary carcinoma tissueis much higher than that in stage III and IV, while the positive rate of MDM2 in Stage I and II ovary carcinoma tissue is markedly lower than that in Stage III and IV. It suggests that deletion or weak expression of PTEN and over-expression of MDM2 have close correlation with the development of ovary carcinoma and lymphatic metastasis. It also indicates that PTEN and MDM2 can be valued as biological index of development and prognosis of primary ovary carcinoma.3. The deletion or the weak expression of PTEN has certain relationship with the over-expression of MDM2, which supports the foundation of path PTEN-PI3K-AKT/PKB-MDM2-p53/PRb/E2F. It supposed that the abnormal signal conduct path-way plays a certain role in the occurrence and development of ovary carcinoma. The abnormal suppress of the two genes disturbs the signal conduct path, which lead to the occurrence of nephroblastoma.